# SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer

> **NCT04408898** · PHASE2 · WITHDRAWN · sponsor: **Adaptimmune**

## Conditions studied

- Head and Neck Cancer

## Interventions

- **GENETIC:** ADP-A2M4 in combination with pembrolizumab.

## Key facts

- **NCT ID:** NCT04408898
- **Lead sponsor:** Adaptimmune
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-07-02
- **Primary completion:** 2021-12
- **Final completion:** 2021-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Challenges with recruitment
- **Last updated:** 2021-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04408898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04408898, "SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT04408898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*